Kinnate Biopharma Inc expected to post a loss of 77 cents a share - Earnings Preview

Kinnate Biopharma

09/08/2023 03:04

* Kinnate Biopharma Inc  KNTE.OQ   KNTE.O  is expected
to show no
change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Kinnate Biopharma
Inc is
for a loss of 77 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 7.1%
in the last three months. ​
    * Wall Street's median 12-month price target for Kinnate
Biopharma
Inc is $22​, above​ its last closing price of $2.64. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.78       -0.75                        
 Mar. 31 2023  -0.70       -0.73      -0.73     Met     0
 Dec. 31 2022              -0.72      -0.72     Met     -0.6​
 Sep. 30 2022  -0.60       -0.61      -0.70     Missed  -15.2
 ​​Jun.        -0.66       -0.64      -0.62     Beat    2.9
 30 2022                                                
 Mar. 31 2022  -0.62       -0.61      -0.61     Met     -0.5​
 Dec. 31 2021  -0.60       -0.59      -0.60     Missed  -2.2
 Sep. 30 2021  -0.55       -0.54      -0.57     Missed  -5.6
 This summary was machine generated August 9 at 02:03 GMT.  All
figures in US dollars  unless otherwise stated